Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regulatory T cells for immune hyperactivation in COVID-19 and/or ARDS
2024-519799-25-00Phase 2Authorised
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of autologous regulatory T-lymphocytes in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and Immune hyperactivation, sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Planned start Jan 2025; status: authorised.
02
Drugs
autologous regulatory T-lymphocytes
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)Immune hyperactivation
Beyond the preview
Go deeper on 2024-519799-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519799-25-00.